Publication | Open Access

Phase II trial of two different irinotecan schedules with pharmacokinetic analysis in patients with recurrent glioma: North Central Cancer Treatment Group results

Recurrent GliomaOncologyPhase Ii TrialMedicineMetronomic TherapyPharmacotherapyHigh-grade GliomasCancer TreatmentPharmacologyGliomaDifferent Irinotecan SchedulesCancer Research